- Home
- STKS vs UNCY Comparison
STKS vs UNCY Comparison
Compare STKS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- UNCY
- Stock Information
- Founded
- STKS 2004
- UNCY 2016
- Country
- STKS United States
- UNCY United States
- Employees
- STKS N/A
- UNCY N/A
- Industry
- STKS Restaurants
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- STKS Consumer Discretionary
- UNCY Health Care
- Exchange
- STKS Nasdaq
- UNCY Nasdaq
- Market Cap
- STKS 77.7M
- UNCY 74.2M
- IPO Year
- STKS N/A
- UNCY 2021
- Fundamental
- Price
- STKS $1.90
- UNCY $4.38
- Analyst Decision
- STKS Hold
- UNCY Strong Buy
- Analyst Count
- STKS 3
- UNCY 5
- Target Price
- STKS $4.50
- UNCY $41.60
- AVG Volume (30 Days)
- STKS 68.8K
- UNCY 459.6K
- Earning Date
- STKS 11-06-2025
- UNCY 11-14-2025
- Dividend Yield
- STKS N/A
- UNCY N/A
- EPS Growth
- STKS N/A
- UNCY N/A
- EPS
- STKS N/A
- UNCY N/A
- Revenue
- STKS $834,363,000.00
- UNCY N/A
- Revenue This Year
- STKS $26.58
- UNCY N/A
- Revenue Next Year
- STKS $5.37
- UNCY $19,392.60
- P/E Ratio
- STKS N/A
- UNCY N/A
- Revenue Growth
- STKS 96.64
- UNCY N/A
- 52 Week Low
- STKS $1.86
- UNCY $3.71
- 52 Week High
- STKS $5.26
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- STKS 25.42
- UNCY 42.84
- Support Level
- STKS $2.49
- UNCY $4.32
- Resistance Level
- STKS $2.44
- UNCY $4.63
- Average True Range (ATR)
- STKS 0.14
- UNCY 0.29
- MACD
- STKS -0.06
- UNCY -0.08
- Stochastic Oscillator
- STKS 6.33
- UNCY 8.55
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.